The Japanese phase 3 ABSOLUTE trial revealed that the median overall survival (OS) with albumin-bound paclitaxel was non-inferior to solvent-based paclitaxel, leading to its approval in Japan for the second-line treatment of advanced gastric cancer (23). The gene discussed is ALB; the disease is gastric cancer.